BIO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
BIO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Bio-Rad Laboratories has the Financial Strength Rank of 7.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.Bio-Rad Laboratories's Interest Coverage for the quarter that ended in Sep. 2024 was 5.30. Bio-Rad Laboratories's debt to revenue ratio for the quarter that ended in Sep. 2024 was 0.46. As of today, Bio-Rad Laboratories's Altman Z-Score is 3.00.
For the Medical Devices subindustry, Bio-Rad Laboratories's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Financial Strength distribution charts can be found below:
* The bar in red indicates where Bio-Rad Laboratories's Financial Strength falls into.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
Bio-Rad Laboratories's Interest Expense for the months ended in Sep. 2024 was $-12 Mil. Its Operating Income for the months ended in Sep. 2024 was $64 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was $1,200 Mil.
Bio-Rad Laboratories's Interest Coverage for the quarter that ended in Sep. 2024 is
Interest Coverage | = | -1 | * | Operating Income (Q: Sep. 2024 ) | / | Interest Expense (Q: Sep. 2024 ) |
= | -1 | * | 64.466 | / | -12.174 | |
= | 5.30 |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
Bio-Rad Laboratories's Debt to Revenue Ratio for the quarter that ended in Sep. 2024 is
Debt to Revenue Ratio | = | Total Debt (Q: Sep. 2024 ) | / | Revenue | ||
= | (Short-Term Debt & Capital Lease Obligation | + | Long-Term Debt & Capital Lease Obligation) | / | Revenue | |
= | (1.262 | + | 1200.062) | / | 2598.916 | |
= | 0.46 |
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
Bio-Rad Laboratories has a Z-score of 3.00, indicating it is in Safe Zones. This implies the Z-Score is strong.
Good Sign:
Altman Z-score of 3 is strong.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Bio-Rad Laboratories (NYSE:BIO) Financial Strength Explanation
The maximum rank is 10. Companies with rank 7 or higher will be unlikely to fall into distressed situations. Companies with rank of 3 or less are likely in financial distress.
Bio-Rad Laboratories has the Financial Strength Rank of 7.
Thank you for viewing the detailed overview of Bio-Rad Laboratories's Financial Strength provided by GuruFocus.com. Please click on the following links to see related term pages.
Tania Devilliers | officer: INT PRIN ACCTG OFC | C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547 |
Sedat Evran | officer: EVP, Global Supply Chain | C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547 |
Corey Colleen | officer: EVP, Global Human Resources | 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547 |
Diane Dahowski | officer: EVP, Global Supply Chain | C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547 |
Schwartz Allison | director | C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547 |
Simon May | officer: EVP, President, LSG | C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547 |
Andrew J. Last | officer: EVP, Chief Operating Officer | 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051 |
Ajit Ramalingam | officer: SVP, Chief Accounting Officer | C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547 |
Ilan Daskal | officer: EVP, Chief Financial Officer | 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547 |
Timothy S Ernst | officer: EVP, General Counsel & Sec | 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547 |
Dara Wright | officer: Executive Vice President | C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547 |
Michael Crowley | officer: EVP, GBL Commercial Operations | 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547 |
Steven D Schwartz | 10 percent owner | 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547 |
Alice N Schwartz | director, 10 percent owner | |
Norman D Schwartz | director, 10 percent owner, officer: Chairman, President, and CEO | 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547 |
From GuruFocus
By Business Wire • 08-22-2024
By Business Wire • 08-20-2024
By GuruFocus Research • 09-20-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 01-22-2024
By GuruFocus Research • 02-15-2024
By Business Wire • 07-17-2024
By Business Wire • 03-20-2024
By GuruFocus Research • 05-07-2024
By Business Wire • 04-18-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.